New data supporting the safety and efficacy of tapinarof cream 1% (Vtama; Organon) for pediatric patients with atopic ...
Michael Hassett, MD, explains the evolving landscape of HER2-positive breast cancer treatment and the role of CDK inhibition ...
The FDA approved the combination of pembrolizumab (Keytruda) and enfortumab vedotin-ejfv (Padcev) for neoadjuvant and ...
Genetic predisposition to rheumatoid arthritis increases the risk of interstitial lung disease by 15.5%, as shown by Mendelian randomization analysis. The study used 52 single nucleotide polymorphisms ...
Despite untreated HBV being linked to earlier mortality, higher all-cause and liver-related death, and a 10% to 25% lifetime risk of developing hepatocellular carcinoma (HCC), only 29% of qualifying ...
Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability. Stay ahead of ...
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health ...
Encouraging the use of pre-exposure prophylaxis (PrEP) depends on the way that HIV risk is communicated to subgroups that are traditionally at the highest risk. A new study found that interest in PrEP ...
The FDA today approved selumetinib (Koselugo; Alexion, AstraZeneca Rare Disease) for the treatment of adults with ...
Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.
Remibrutinib showed rapid and sustained efficacy in CSU, with significant symptom reduction by week 2, maintained over 52 weeks. The pooled analysis of REMIX-1 and REMIX-2 trials highlighted ...
Panelists discuss how the Inflation Reduction Act (IRA) introduces landmark changes to drug pricing through its negotiation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback